The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Low-dose THC beverages typically contain somewhere between 2 and 5 mg of THC per serving.…
A few dozen strangers answered one question, and here's what they told me. Cannabis rarely…
Federal officials admitted under oath at the DEA marijuana rescheduling hearing that the 54-year-old test…
Discover why Donald Trump lost the 2026 midterms, how the hemp and cannabis industries survived…
On October 29, Fox News ran a column by Dr. Marc Siegel, the network’s senior medical…
Is cannabis a miracle cure or a gateway to ruin? We break down the latest…